Belite Bio Investor Relations Material

Belite Bio, Inc. is a clinical-stage biopharmaceutical company engaged in developing novel therapeutics targeting retinal degenerative eye diseases and certain metabolic diseases. The company's primary focus includes conditions such as atrophic age-related macular degeneration (AMD) and autosomal recessive Stargardt disease type 1 (STGD1), which can lead to permanent blindness. Additionally, Belite Bio is exploring treatments for metabolic disorders like non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. Belite Bio, Inc. was founded in 2016 and is headquartered in San Diego, California. The company's shares are listed on the NASDAQ.